<i>Rhodotorula</i> fungemia: A series of four cases. [PDF]
Dallali A +6 more
europepmc +1 more source
Antifungal resistance and poor clinical outcome rates of <i>Candida auris</i> in mainland China: A systematic review and meta-analysis. [PDF]
Xu T, Wang R, Gao Y, Yang L.
europepmc +1 more source
Rezafungin Versus Caspofungin in Candidaemia and Invasive Candidiasis: A Post Hoc Pooled Analysis of Phase 2 and Phase 3 Trials. [PDF]
Soriano A +12 more
europepmc +1 more source
Successful treatment of severe influenza-associated pulmonary aspergillosis with invasive tracheobronchitis and bronchial asthma using combination antifungals and omalizumab: A case report. [PDF]
Du W, Lv H, Ni Y, Ding Y.
europepmc +1 more source
In Vitro Activity and In Vivo Efficacy in a Murine Model of Rezafungin, Anidulafungin, Caspofungin, and Micafungin Against the Fifth Clade of <i>Candida</i> (<i>Candidozyma</i>) <i>auris</i>. [PDF]
Balázsi D +8 more
europepmc +1 more source
Rapid Succession of Multidrug-Resistant Bacteremia and Candidemia in a Patient with Refractory Pemphigus Vulgaris: A Lethal Therapeutic Challenge. [PDF]
Li L, Jiang C.
europepmc +1 more source
In Vitro Anti-<i>Aspergillus</i> Activity and Antifungal Interactions of Monoclonal Antibodies 1D2 and 4E4. [PDF]
Lian X +4 more
europepmc +1 more source
Comparative real-world safety profiles of caspofungin, micafungin, and anidulafungin: a disproportionality analysis based on FAERS and VigiAccess databases. [PDF]
Chen J +6 more
europepmc +1 more source
Multidrug Resistance and Host Adaptation in Candida Auris: From Molecular Mechanisms to Emerging Therapeutic Frontiers. [PDF]
Shao F, Wu T, Su J.
europepmc +1 more source
Correction: Comparative real-world safety profiles of caspofungin, micafungin, and anidulafungin: a disproportionality analysis based on FAERS and VigiAccess databases. [PDF]
Chen J +6 more
europepmc +1 more source

